HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

De novo non-alcoholic fatty liver disease following orthotopic liver transplantation.

Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized clinico-pathologic entity typically associated with obesity, type II diabetes and hyperlipidemia. It has been noted to recur after orthotopic liver transplantation (OLT). We report four patients who developed de novo NAFLD within 3 months of OLT without the typical predisposing factors of diabetes mellitus or obesity. Three of the four patients underwent OLT for hepatitis C-related cirrhosis, and the other for alcoholic cirrhosis. Examination of the liver explants revealed no evidence of steatosis. No surreptitious alcohol use or a drug-induced process could be identified in these patients. Treatment of recurrent hepatitis C infection in one patient with interferon and ribavirin led to sustained suppression of the viral RNA to undetectable levels, but no improvement in histology or liver enzymes. All four patients had histologic evidence of preservation injury on the initial post-OLT biopsies, but the significance of this finding in relationship to the development of NAFLD is unknown. NAFLD can develop without any of the known predisposing conditions after transplantation, and this raises further questions about the pathogenesis of this condition.
AuthorsFred Poordad, Robert Gish, Adil Wakil, Richard Garcia-Kennedy, Paul Martin, Francis Y Yao
JournalAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (Am J Transplant) Vol. 3 Issue 11 Pg. 1413-7 (Nov 2003) ISSN: 1600-6135 [Print] United States
PMID14525603 (Publication Type: Case Reports, Journal Article)
Chemical References
  • RNA, Viral
Topics
  • Adult
  • Fatty Liver (complications, etiology)
  • Female
  • Hepatitis C (complications, virology)
  • Humans
  • Liver Cirrhosis (complications, therapy)
  • Liver Diseases (complications, therapy)
  • Liver Transplantation
  • Male
  • Middle Aged
  • Postoperative Complications
  • RNA, Viral (metabolism)
  • Risk Factors
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: